Pinotbio Inc. has synthesized antibody-drug conjugates comprising an antibody covalently linked to DNA topoisomerase I inhibitors through a cleavable linker reported to be useful for the treatment of cancer.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described C-C chemokine receptor type 6 (CCR6) antagonists reported to be useful for the treatment of asthma, psoriasis, Crohn’s disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.
Latvian Institute of Organic Synthesis has identified selenium compounds acting as estrogen receptor α (ER-α; ESR1) modulators reported to be useful for the treatment of cancer.
Purdue Research Foundation has synthesized proteolysis targeting chimeras (PROTACs) comprising a E3 ubiquitin ligase binding moiety covalently linked to a tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and 2 (PTPN2; TCPTP) dual targeting moiety reported to be useful for the treatment of cancer, type 2 diabetes and obesity.
Type6 Therapeutics Inc. has disclosed cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease and inflammatory disorders.
The U.S. Congress is examining legislative language to address what some believe is a deteriorating state of jurisprudence for injunction when infringement is found in patent litigation.
Researchers from the University of Arkansas have filed for protection of their development of systems and methods to aid angioplasty procedures in coronary artery bifurcations, where a major artery splits into smaller blood vessels.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have reported new glucagon-like peptide 1 receptor (GLP-1R) agonists described as potentially useful for the treatment of diabetes, obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).
RSS
